XML 108 R94.htm IDEA: XBRL DOCUMENT
v3.24.3

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 2,510 | $ 2,238 | $ 7,066 | $ 6,349
Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,198 | 999 | 3,220 | 2,768
Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 567 | 494 | 1,626 | 1,469
OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 472 | 457 | 1,398 | 1,313
Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 245 | 263 | 746 | 731
Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 28 | 25 | 76 | 68
Salix |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 642 | 614 | 1,699 | 1,667
Salix | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 642 | 613 | 1,698 | 1,668
Salix | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 1 | 1 | (1)
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 291 | 275 | 832 | 781
International | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 63 | 63 | 184 | 178
International | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
International | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 50 | 47 | 131 | 125
International | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 161 | 151 | 469 | 438
International | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 17 | 14 | 48 | 40
Solta Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 112 | 83 | 302 | 244
Solta Medical | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 112 | 83 | 302 | 244
Solta Medical | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Diversified |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 269 | 259 | 722 | 684
Diversified | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 246 | 210 | 637 | 567
Diversified | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Diversified | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 2 | 5 | 6
Diversified | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 14 | 40 | 65 | 92
Diversified | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 7 | 7 | 15 | 19
Bausch + Lomb |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,196 | 1,007 | 3,511 | 2,973
Bausch + Lomb | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 247 | 113 | 701 | 355
Bausch + Lomb | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 455 | 411 | 1,324 | 1,225
Bausch + Lomb | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 420 | 408 | 1,262 | 1,182
Bausch + Lomb | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 70 | 72 | 212 | 201
Bausch + Lomb | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 4 | $ 3 | $ 12 | $ 10

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |